ramatroban
Small moleculeexperimental
Ramatroban (INN; also known as BAY u3405) is a thromboxane receptor antagonist. It is also a DP2 receptor antagonist. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2005 (NCT00311051)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- G protein-coupled receptor 44ANTAGONIST
G protein-coupled receptor 44 antagonist
- Thromboxane A2 receptorANTAGONIST
Thromboxane A2 receptor antagonist
- Thromboxane A2 receptorINHIBITOR
TBXA2R inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2- Mol. weight
- 416.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaRamatroban ↗
- ChEMBLCHEMBL361812 ↗
Also known as
- 3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid
- 9h-carbazole-9-propanoic acid, 3-(((4-fluorophenyl)sulfonyl)amino)-1,2,3,4-tetrahydro-, (r)-
- baynas
- bay u3405
- bay u 3405
- bay u-3405
- bay-u-3405
- bay-u-3405
- bay u 3406
- en-137774
- en-137774
- ramatroban
- ramatroban
- ramatroban
- ramatroban
- ramatroban
- ramatroban
- ramatroban
- ramatroban
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00311051 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2005 | Research Center Borstel |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Research Center Borstel | Academic/Hospital | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1